This inventor holds 1 USPTO granted patent. Top assignee: Mereo Biopharma 1 Limited. Active years: 2023.
Company Filing History:
Years Active: 2023
Title: Alastair MacKinnon: Innovator in Pharmaceutical Treatments
Introduction
Alastair MacKinnon is a notable inventor based in London, GB. He has made significant contributions to the field of pharmaceuticals, particularly in the treatment of chronic obstructive pulmonary disease (COPD). His innovative work has led to the development of a unique pharmaceutical composition aimed at improving patient outcomes.
Latest Patents
Alastair MacKinnon holds a patent for the use of 3-[5-amino-4-(3-cyanobenzoyl)-pyrazol-1-yl]-N-cyclopropyl-4-methylbenzamide in the treatment of acute exacerbations of chronic obstructive pulmonary disease. This invention relates to pharmaceutical compositions that are specifically designed for human patients with less than 2% blood eosinophils. The patent outlines a method of administering three separate therapeutically effective doses of the compound over a period of no longer than ten days, ensuring optimal treatment efficacy.
Career Highlights
MacKinnon is currently associated with Mereo Biopharma 1 Limited, where he continues to advance his research and development efforts. His work focuses on creating innovative solutions for complex medical conditions, showcasing his commitment to improving healthcare.
Collaborations
One of his notable collaborators is Jacqueline Parkin, with whom he has worked closely to further their shared goals in pharmaceutical innovation.
Conclusion
Alastair MacKinnon is a distinguished inventor whose contributions to the field of pharmaceuticals are noteworthy. His patent for a novel treatment for COPD exemplifies his dedication to enhancing patient care through innovative solutions.